芯原股份 reported revenue of ¥1.86B for the period ended 2026-06-30, +91.4% year on year. Net income was ¥-0.61B, a -32.8% net margin on a 31.3% gross margin. The largest revenue line is 量产服务收入 at 62% of the total. Free cash flow for the period was ¥0.87B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.86B | +91.4% |
| Gross profit | ¥0.58B | — |
| Operating income | ¥-0.60B | — |
| Net income | ¥-0.61B | — |
| Gross margin | 31.3% | Net margin -32.8% |
| Revenue Q/Q | +23.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 量产服务收入 | ¥1.16B | 62.4% |
| 设计服务收入 | ¥0.35B | 18.8% |
| IP授权使用费收入 | ¥0.29B | 15.7% |
| IP特许权使用费收入 | ¥0.06B | 3.0% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.28B | 68.7% |
| R&D | ¥0.88B | 47.2% |
| SG&A | ¥0.22B | 11.8% |
| Tax & other | ¥0.01B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥9.06B |
| Total liabilities | ¥6.14B |
| Shareholders' equity | ¥2.93B |
| Equity / assets | 32.3% |
| Operating cash flow | ¥0.93B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥0.87B |
| Cash conversion (OCF / net income) | -102% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中芯国际 ・ 特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies